
Pregaba50 mg
Opsonin Pharma Ltd.
Pregabalin is indicated for the following conditions: Established / FDA-approved uses Neuropathic pain associated with diabetic peripheral neuropathy (DPN) Postherpetic neuralgia (PHN) — nerve pain…
Pregabalin is indicated for the following conditions:
Use of Pregabalin should always be guided by a qualified physician based on individual diagnosis.
Dosing of Pregabalin is individualized by indication, renal function, and patient response. Doses should be titrated gradually to reduce the risk of dizziness and somnolence.
| Indication | Starting dose | Titration | Maximum dose |
|---|---|---|---|
| Diabetic peripheral neuropathy | 50 mg 3 times/day (150 mg/day) | May increase to 100 mg 3 times/day within 1 week based on response/tolerability | 300 mg/day |
| Postherpetic neuralgia | 75 mg twice/day or 50 mg 3 times/day (150 mg/day) | May increase to 300 mg/day within 1 week; up to 600 mg/day after 2-4 weeks if pain is inadequately controlled and the dose is tolerated | 600 mg/day |
| Fibromyalgia | 75 mg twice/day (150 mg/day) | May increase to 150 mg twice/day within 1 week; further increase to 225 mg twice/day if needed | 450 mg/day |
| Adjunctive therapy, partial-onset seizures (adults) | 150 mg/day in 2-3 divided doses | May increase weekly based on response/tolerability | 600 mg/day |
| Neuropathic pain, spinal cord injury | 75 mg twice/day (150 mg/day) | May increase to 150 mg twice/day within 1 week; up to 300 mg twice/day after 2-3 weeks if needed and tolerated | 600 mg/day |
Dosing is weight-based (approximately 3.5-14 mg/kg/day in divided doses depending on age and body weight), started at a low dose and titrated gradually; see full prescribing information for the age/weight-specific schedule. Safety and efficacy for other indications (neuropathic pain, fibromyalgia) have not been established in patients under 18 years.
| Creatinine clearance (CrCl) | Dose adjustment |
|---|---|
| ≥60 mL/min | No adjustment; use standard dosing |
| 30-60 mL/min | Reduce total daily dose by ~50% |
| 15-30 mL/min | Reduce total daily dose by ~75% |
| <15 mL/min | Reduce total daily dose by ~87.5% (lowest effective dose) |
| Hemodialysis | Supplemental dose after each 4-hour hemodialysis session |
Extended-release Pregabalin is not recommended in patients with CrCl below 30 mL/min. No dose adjustment is required for hepatic impairment, as Pregabalin undergoes negligible hepatic metabolism.
When discontinuing Pregabalin, the dose should be tapered gradually over a minimum of 1 week rather than stopped abruptly (see Precautions and Warnings).
Common side effects of Pregabalin (may affect more than 1 in 10 people) include:
Less common but serious side effects — seek prompt medical attention if these occur:
Pregabalin is contraindicated in patients with a known history of hypersensitivity to Pregabalin or any of its formulation components — reactions have included angioedema and generalized hypersensitivity (e.g., dyspnea, wheezing, rash).
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.